IPM514 / Immupeutics Medicine - LARVOL DELTA

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma. (PubMed, NPJ Vaccines) - "Importantly, combination therapy with PD-1 blockade augmented antitumor efficacy by promoting immune cell infiltration, upregulating antigen presentation pathways, and reprogramming the tumor microenvironment toward an anti-tumorigenic state. These results demonstrate IPM514 represents a promising novel mRNA vaccine strategy for improving ESCC immunotherapy."

Journal • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Beijing Immupeutics Medicine Technology Limited

New P1 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma